Gold Readies for 6th Straight Weekly Gain
Gold prices hovered near record-high levels Friday and set for a sixth successive weekly gain, as trade war concerns fueled safe-haven buying ahead of the key U.S. payrolls report.Spot gold was up 0.4% at $2,867.69 U.S. per ounce early Friday, and has gained more than 2% this week. Bullion hit an all-time high at $2,882.16 on Wednesday.U.S. gold futures gained 0.5% to $2,889.80.Earlier this week, the World Trade Organization said China initiated a dispute over the U.S. tariffs.Goldman Sachs said they see upside risk to their $3,000 target from a potentially persistent boost from elevated U.S. policy uncertainty to central bank and investor hedging demand.Focus now shifts to the U.S. employment report, due at 8:30 EST, which investors will scan for any hints on the U.S. interest rate cycle.A full-employment economy with solid growth and falling inflation will let the Federal Reserve continue cutting rates, though uncertainty about the impact of tariffs and other policy changes argues for a slower approach. Gold is considered a safe investment during economic and geopolitical turmoil, but higher interest rates reduce the non-yielding asset’s appeal.Elsewhere, spot silver added 0.2% to $32.26 U.S. per ounce and platinum increased 0.6% to $991.10, while palladium shed 0.2% to $976.25 U.S.Both silver and platinum were seen rising this week, while palladium was headed for a weekly loss.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


